UiPath Slides 24% After Q2 Earnings: Is PATH Stock a Buy?

UiPath reported fiscal Q2 2027 revenue of $410.3 million, up 13.4% year over year and 3.1% above consensus, while achieving $31.6 million of GAAP operating income and a fourth consecutive profitable quarter. Full-year revenue guidance was raised by roughly 0.7% at the midpoint to $1.789-$1.794 billion and non-GAAP operating-income guidance increased 3.5% to $445 million, but Q3 revenue guidance of $440-$445 million fell slightly below the $444.3 million consensus. Shares have declined 24% since the results as investors focus on only a modest ARR-guidance increase and competitive AI risks from ServiceNow and Salesforce, despite UiPath's $1.405 billion cash-and-investments balance and no debt.

Analysis

PATH’s investment case is transitioning from a growth-duration asset to an execution-and-cash-conversion story. The key underwriting question is whether AI raises automation attach rates and contract values faster than it commoditizes basic RPA; current evidence supports strategic relevance but not yet a reacceleration in net-new demand. The decline in cash generation and gross-margin pressure matter more than the operating-profit beat, because both can indicate that implementation intensity, cloud costs, or commercial concessions are rising as UiPath sells broader AI-enabled outcomes.

Competitive risk is asymmetric: NOW and CRM can bundle workflow automation into much larger platform contracts, reducing procurement friction and potentially compressing PATH’s standalone pricing. Conversely, their platform focus leaves a credible niche for PATH in regulated, cross-application processes where auditability, deterministic execution and vendor-neutral orchestration are required. The second-order beneficiary of a successful PATH pivot would be enterprise AI infrastructure spending, but PATH must prove it can capture a meaningful portion of that budget rather than merely integrate third-party models at lower incremental margin.

Over the next 1-3 months, the relevant catalyst is evidence that new AI-led deployments convert into larger subscriptions rather than professional-services-heavy projects. For the 6-18 month thesis, retention must remain stable or improve while ARR growth reaccelerates; otherwise the market is likely to value PATH primarily on its cash balance and mature-software multiple. The bullish case is not validated by another modest guidance raise: it requires sequential net-new ARR expansion, stable-to-higher gross margin, and free-cash-flow normalization. A sustained deterioration in retention, another gross-margin step-down, or AI deal activity failing to translate into ARR would falsify the thesis.

Key Decisions for Investors

• Maintain PATH as a watch-to-buy rather than chase the post-selloff narrative: initiate a starter long only if the next print shows sequential improvement in net-new ARR and no further gross-margin erosion. Add on confirmation that AI-related wins are converting into recurring subscription ARR; target a 6-12 month holding period.
• Express relative-value exposure via long PATH / short IGV in modest size if broad software multiples remain elevated. This isolates a potential company-specific execution recovery while reducing duration and AI-software beta; exit if PATH retention weakens or ARR growth fails to improve over the next two reporting periods.
• Avoid a direct PATH versus NOW or CRM pair short absent valuation and positioning data. NOW and CRM have stronger distribution, larger installed bases and bundling capacity, so a PATH recovery can coexist with continued relative outperformance by the platform incumbents.
• Set an earnings alert around three metrics: sequential net-new ARR above the prior-quarter run rate, dollar-based net retention above 109%, and adjusted free-cash-flow recovery. Failure on two of the three should move PATH from accumulation candidate to avoid, regardless of reported EPS upside.